query,Intended Stakeholder,What to Observe,Business Outcome Signal
"Summarize recent Phase III results comparing semaglutide vs. liraglutide for Type 2 diabetes","Medical Affairs","Ranked trials with dosage differences and efficacy endpoints","Shows ability to prep HCP talking points in <5 minutes"
"Are there documented interactions between rivaroxaban and azole antifungals?","Pharmacovigilance","Safety alert section plus source citations","Demonstrates proactive risk monitoring"
"What evidence supports payer coverage for new RSV prophylaxis in adults over 65?","Market Access","Synthesis highlighting real-world outcomes and cost data","Illustrates dossier-ready insight generation"
